Expanding Our Capabilities: Full Characterization & Development for Recombinant Proteins
In 2025, we have invested significantly in strengthening our protein platform. As part of this expansion, we’ve added Liquid Chromatography–Mass Spectrometry (LC-MS) to our technology suite — enabling deeper, more accurate insights into your protein.
With the new LC-MS equipment, our team can characterize proteins in far greater detail, including: identity, purity profiles, post-translational modifications, and glycan profiling.
This enhanced analytical power offers a stronger foundation for development work and provides the data you need to make confident decisions throughout your project.
Earlier this year…
Earlier this year, we also invested in the newest Ambr250 high-throughput bioreactor system, enabling accelerated upstream development and de-risked scale-up for biologics production. Together, these technologies allow us to support your pathway from early design to a well-defined, scalable process.
How we work as your partner
Our protein team consists of a dedicated group of specialists with deep experience working with complex proteins. What sets us apart from larger players is our approach:
- Fast project initiation
- Flexible packages with go/no-go decision points
- Co-created solutions tailored to your needs
- Direct access to expert scientists
We aim to be a partner who moves quickly, listens closely, and personalizes every project.
Check if you´re a fit for the BioStart Package
We know it’s not the easiest time to be a small biotech company. That’s why we made a custom-designed BioStart package to support you at every step in your early-phase drug development. Get the details on what’s included here.
